Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Anvumetostat in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion

NCT06360354 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06360354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06360354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Anvumetostat in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 29, 2024
Completion date
November 30, 2026
Enrollment
120 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastrointestinal, biliary tract, and pancreatic cancers